Expertise in
15
conditions

Dr. Vaishali H. Sanchorawala

Hematology
Boston University Medical Center Radiologists Inc.
840 Harrison Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
Boston University Medical Center Radiologists Inc.
840 Harrison Ave, 
Boston, MA 

Overview

Vaishali Sanchorawala is a Hematologist practicing medicine in Boston, Massachusetts.

Dr. Sanchorawala is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, Cardiac Amyloidosis, Multiple Myeloma, Bone Marrow Transplant, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 232 peer reviewed articles and participating in 11 clinical trials. Dr. Sanchorawala is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MA

Hospital Affiliations

Boston Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Boston University Medical Center Radiologists Inc.
840 Harrison Ave, Boston, MA 02118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis
A Phase 1/1a Study of Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Dexamethasone, Ixazomib Citrate, Venetoclax
Study Phase: Phase 1
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drugs: Daratumumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis
Enrollment Status: Completed
Publish Date: September 09, 2025
Intervention Type: Other, Biological
Study Drug: Isatuximab
Study Phase: Phase 2
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis
Enrollment Status: Completed
Publish Date: January 07, 2025
Intervention Type: Other, Drug, Biological, Procedure
Study Drugs: Anti-thymocyte globulin, Cyclophosphamide, Filgrastim, Mycophenolate mofetil, Plerixafor
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease
Enrollment Status: Terminated
Publish Date: May 09, 2023
Intervention Type: Drug, Other
Study Drugs: Pomalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 1
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection
Enrollment Status: Completed
Publish Date: January 20, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Enrollment Status: Terminated
Publish Date: March 28, 2022
Intervention Type: Drug
Study Drugs: Melphalan-Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 1
A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis
Enrollment Status: Completed
Publish Date: May 07, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

232 Total Publications

Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
19
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (1.8 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (1.8 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Cutler is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

Expertise in
15
conditions
Expertise in
15
conditions
Referral may be required

Tufts Medical Center Hematology

860 Washington St Bldg 7, 
Boston, MA 
 (1.3 miles away)
617-263-8312
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raymond Comenzo is a Hematologist practicing medicine in Boston, Massachusetts. Dr. Comenzo is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Cardiac Amyloidosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Comenzo is currently accepting new patients.

Frequently Asked Questions about Dr. Vaishali H. Sanchorawala

How do I make an appointment with Dr. Vaishali H. Sanchorawala?

You can book an appointment with Dr. Vaishali H. Sanchorawala by calling their office at 617-414-5673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vaishali H. Sanchorawala a top-rated expert for Primary Amyloidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vaishali H. Sanchorawala is classified as an Elite expert for Primary Amyloidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vaishali H. Sanchorawala specialize in?

While Dr. Vaishali H. Sanchorawala is a Hematology, they have specific expertise in Primary Amyloidosis, Cardiac Amyloidosis, and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Vaishali H. Sanchorawala participate in research or clinical trials?

Yes. Dr. Vaishali H. Sanchorawala has published 232 articles and abstracts on conditions like Primary Amyloidosis. You can view a list of Dr. Vaishali H. Sanchorawala's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vaishali H. Sanchorawala accept my insurance?

Dr. Vaishali H. Sanchorawala accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-414-5673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sanchorawala's expertise for a condition
ConditionClose
View All 10 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile